Anti-BTLA Agonist Therapy in Subjects With Primary Sjogren's Syndrome
Status:
Not yet recruiting
Trial end date:
2025-12-01
Target enrollment:
Participant gender:
Summary
This will be a single-site, open-label study in patients with primary Sjogren's syndrome. The
aim of this clinical trial is to evaluate the safety and efficacy of anti-BTLA agonist
therapy (LY3361237) in treating patients with primary Sjogren's syndrome.
The primary objective is to evaluate the efficacy of LY3361237 in patients with primary
Sjogren's syndrome by assessing changes in the Sjogren's Tool for Assessing Response (STAR)
after 12 weeks of treatment.
The secondary objective is to determine the effect of LY3361237 on glandular changes measured
by PET/MRI.